[Antirheumatic therapy with new non-steroidal compounds (author's transl)].
Non-steroidal antirheumatic agents have the same type of action qualitatively: they are more or less potent inhibitors of prostaglandin synthesis and also influence other mediators of the inflammatory process. Certain risks with these substances are the inevitable side-effects of their antiinflammatory/analgesic action. Experiments to improve this type of substance have, however, produced undoubted advances in longterm treatment with antirheumatic agents: the daily therapeutic doses could be markedly reduced, the dosage scheme became simpler and consequently compliance-orientated. With demonstrably effective tissue levels at the site of the inflammation they have a sustained action on the symptoms of rheumatic diseases.
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008134:Long-Term Care; D010349:Patient Compliance; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D011448:Prostaglandin Antagonists
Antirheumatische Therapie mit neuen nichtsteroiden Wirkstoffen.